Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: May 6, 2009

Premium

El Camino Hospital has appointed Paul Billings as acting director and chief science officer of its new Genomic Medicine Institute. Billings is co-founder of GeneSage; co-founder and first medical director of CBR Systems; and advisor for CELLective Dx Corporation. He was previously VP of corporate development and senior geneticist at the Laboratory Corporation of America and an adjunct professor in the department of anthropology at University of California, Berkeley.


DxS appointed Chief Operating Officer Jeff Devlin to its executive board. Before joining DxS this January, Devlin was executive VP of Shire Pharmaceuticals and a partner at Ernst & Young's life sciences division.

Additionally, Peter Collins has been appointed senior VP of business development at DxS. Previously, Collins has held senior executive roles at Vysis, a subsidiary of Abbott Molecular Diagnostics; Quantase, a subsidiary of Bio-Rad Laboratories; as well as Gentronix, Biogenex, and Pronostics.

Filed under

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more